Gamco Investors INC. ET AL continued to hold its stake in Nuvectra Corp (NASDAQ:NVTR) during the first quarter, Holdings Channel reports. The firm owned 33,760 shares of the company’s stock at the end of the first quarter. Gamco Investors INC. ET AL owned 0.33% of Nuvectra Corp worth $231,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Wells Fargo & Company MN raised its stake in Nuvectra Corp by 0.7% in the first quarter. Wells Fargo & Company MN now owns 112,997 shares of the company’s stock valued at $772,000 after buying an additional 751 shares during the last quarter. Numeric Investors LLC raised its stake in Nuvectra Corp by 4.2% in the fourth quarter. Numeric Investors LLC now owns 248,461 shares of the company’s stock valued at $1,250,000 after buying an additional 9,965 shares during the last quarter. Essex Investment Management Co. LLC raised its stake in Nuvectra Corp by 17.7% in the first quarter. Essex Investment Management Co. LLC now owns 142,589 shares of the company’s stock valued at $974,000 after buying an additional 21,469 shares during the last quarter. Raffles Associates LP raised its stake in Nuvectra Corp by 20.3% in the third quarter. Raffles Associates LP now owns 214,675 shares of the company’s stock valued at $1,486,000 after buying an additional 36,190 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Nuvectra Corp by 77.7% in the fourth quarter. Renaissance Technologies LLC now owns 86,200 shares of the company’s stock valued at $434,000 after buying an additional 37,700 shares during the last quarter. 61.35% of the stock is owned by institutional investors and hedge funds.
Shares of Nuvectra Corp (NASDAQ:NVTR) opened at 10.81 on Friday. Nuvectra Corp has a 52 week low of $4.63 and a 52 week high of $10.90. The company’s 50 day moving average price is $8.18 and its 200-day moving average price is $6.78. The company’s market capitalization is $111.80 million.
Nuvectra Corp (NASDAQ:NVTR) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.25) by $0.02. The company had revenue of $5 million during the quarter, compared to analysts’ expectations of $4.61 million. Nuvectra Corp had a negative net margin of 320.73% and a negative return on equity of 33.89%. Nuvectra Corp’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.70) earnings per share. Analysts anticipate that Nuvectra Corp will post ($4.56) earnings per share for the current fiscal year.
Several research firms have recently issued reports on NVTR. B. Riley reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Nuvectra Corp in a research note on Wednesday, May 10th. Zacks Investment Research lowered Nuvectra Corp from a “hold” rating to a “sell” rating in a research note on Saturday, May 13th.
In other Nuvectra Corp news, CEO Scott F. Drees acquired 2,605 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was bought at an average cost of $9.92 per share, for a total transaction of $25,841.60. Following the completion of the transaction, the chief executive officer now owns 90,041 shares of the company’s stock, valued at approximately $893,206.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Scott F. Drees acquired 25,000 shares of the stock in a transaction that occurred on Tuesday, March 14th. The stock was acquired at an average price of $6.21 per share, with a total value of $155,250.00. Following the completion of the transaction, the chief executive officer now directly owns 7,900 shares of the company’s stock, valued at approximately $49,059. The disclosure for this purchase can be found here. Insiders bought 52,605 shares of company stock valued at $333,842 over the last 90 days.
Nuvectra Corp Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
Want to see what other hedge funds are holding NVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nuvectra Corp (NASDAQ:NVTR).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/gamco-investors-inc-et-al-maintains-position-in-nuvectra-corp-nvtr/1858566.html
Receive News & Ratings for Nuvectra Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corp and related companies with MarketBeat.com's FREE daily email newsletter.